EXAGEN INC.
Close on Oct 19, 2026
- Market cap
- $179.54M
- P/E (TTM)
- –
- Dividend yield
- –
About Exagen
Services-Medical Laboratories, SIC 8071
Exagen is a medical technology company that develops and commercializes diagnostic, prognostic, and monitoring testing products focused on complex rheumatic and autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis. The company provides a suite of ten commercialized tests under the AVISE brand name, featuring its connective tissue disease panel alongside specialized assays for disease prognosis, vasculitis, and therapeutic drug monitoring. Its testing services support rheumatologists, primary care physicians, other medical specialists, hospitals, and healthcare systems.
The company conducts its operations in the United States, where it utilizes a dedicated sales organization to reach approximately 6,000 rheumatologists nationwide. Testing procedures are conducted through its central specialty laboratory. The provided text does not state the location of the company's headquarters or provide counts of additional facilities.
Summary of the business section of Exagen's latest annual report, written by StockData.
Company profile
Company
- Legal name
- EXAGEN INC.
- Founded
- 2002
- Headquarters
- Vista, CA
- Address
- 1261 Liberty Way 92081
- Phone
- (760) 560-1501
- Website
- exagen.com
- Employees
- 220, Dec 31, 2025
- Industry
- Services-Medical Laboratories
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- BDO USA, P.C., San Diego, California
Stock & identifiers
- Ticker
- XGN
- Exchange
- Nasdaq
- Shares outstanding
- 24M, Jul 30, 2026
- Public float
- $153.60M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1274737
- CUSIP
- 30068X103
- ISIN
- US30068X1037
- LEI
- 549300JV2CYDOME5OO17
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| John Aballi | President and CEO, Director | 880,235 |
| Jeffrey G. Black | Chief Financial Officer | 324,910 |
| Bruce C. Robertson | Director | – |
| Paul Kim | Director | – |
| Chas McKhann | Director | 7,500 |
| Frank Stokes | Director | – |
| Scott D. Kahn | Director | – |
| Ana Hooker | Director | – |
| Tina Susan Nova | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 John Aballi | $1.40M | $2.86M | $746.19K | $253 | – |
| FY2024 John Aballi | $1.18M | $1.98M | $905.66K | $168 | – |
| FY2023 John Aballi | $931.95K | $775.33K | $984.54K | $82 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had a total of 220 employees: 216 full-time employees and 4 part-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 14, 2022 | Late filing | Notification of late filing |
| Sep 13, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |
| May 18, 2017 | Name change | Name changed from EXAGEN DIAGNOSTICS INC to EXAGEN INC. |